Online inquiry

IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5899MR)

This product GTTS-WQ5899MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL31RA gene. The antibody can be applied in Atopic dermatitis (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001242636.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 133396
UniProt ID Q8NI17
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ5899MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1906MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ13651MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ10573MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ5150MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ4454MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ1219MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ6583MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ9537MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J-591
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW